Loading
A phase 3 trial of Pertuzumab in HER2-positive breast cancer, run by Biocad, active and no longer recruiting.
Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer is a phase 3 interventional study registered as NCT05802225 by Biocad, with 398 participants enrolled, started 2023-01-30 and due to reach its primary completion in 2025-06-06. Interventions recorded: BCD-178 and Perjeta.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pertuzumab, HER2-positive breast cancer, Monoclonal antibodies and the tag pipeline.
Shares Early HER2-positive breast cancer, Pertuzumab, HER2-positive breast cancer, Monoclonal antibodies and the tag pipeline.
Shares Pertuzumab, Monoclonal antibodies and the tag pipeline.
Shares Early HER2-positive breast cancer, Pertuzumab, HER2-positive breast cancer and the tag pipeline.
Shares Early HER2-positive breast cancer, HER2-positive breast cancer, Monoclonal antibodies and the tag pipeline.
Shares Biocad and the tag pipeline.
Shares Biocad and the tag pipeline.
Shares Pertuzumab, HER2-positive breast cancer, Monoclonal antibodies and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/